Q2 EPS Estimates for Sage Therapeutics Lifted by Wedbush

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Stock analysts at Wedbush lifted their Q2 2025 earnings per share estimates for shares of Sage Therapeutics in a research note issued on Tuesday, April 29th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn ($0.97) per share for the quarter, up from their prior estimate of ($1.02). Wedbush has a "Neutral" rating and a $6.00 price target on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($3.52) per share. Wedbush also issued estimates for Sage Therapeutics' Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.72) EPS, Q1 2026 earnings at ($0.65) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.60) EPS, Q4 2026 earnings at ($0.55) EPS, FY2026 earnings at ($2.43) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at ($1.09) EPS and FY2029 earnings at ($0.73) EPS.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The company had revenue of $14.06 million during the quarter, compared to analyst estimates of $14.12 million. During the same quarter last year, the company posted ($1.80) EPS. The firm's quarterly revenue was up 78.0% on a year-over-year basis.

Several other research analysts have also recently weighed in on the company. Needham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a research report on Friday, April 25th. Canaccord Genuity Group lowered their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research report on Wednesday, February 12th. StockNews.com raised shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a report on Friday. HC Wainwright reaffirmed a "neutral" rating and set a $12.00 target price (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Bank of America started coverage on Sage Therapeutics in a research note on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 price target for the company. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $8.81.

Sage Therapeutics Stock Performance

Shares of NASDAQ SAGE traded down $0.18 during trading hours on Friday, reaching $7.30. 1,060,063 shares of the stock were exchanged, compared to its average volume of 1,221,130. The firm has a market capitalization of $457.13 million, a price-to-earnings ratio of -1.11 and a beta of 0.20. The stock's fifty day simple moving average is $7.54 and its 200 day simple moving average is $6.78. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $14.31.

Hedge Funds Weigh In On Sage Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SAGE. Thrivent Financial for Lutherans grew its stake in shares of Sage Therapeutics by 108.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company's stock worth $405,000 after buying an additional 38,876 shares during the last quarter. Amundi acquired a new position in Sage Therapeutics in the 4th quarter worth about $166,000. Geode Capital Management LLC grew its holdings in shares of Sage Therapeutics by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock worth $8,975,000 after purchasing an additional 3,757 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Sage Therapeutics by 57.7% in the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company's stock valued at $122,000 after buying an additional 8,228 shares during the period. Finally, Empowered Funds LLC bought a new position in Sage Therapeutics in the 4th quarter valued at approximately $91,000. 99.22% of the stock is currently owned by institutional investors and hedge funds.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.